OpenAI adds sponsored GPT-Rosalind access for academic labs

OpenAI said it is extending GPT-Rosalind to academic research labs through a new Rosalind Academic Plan, a sponsored-access program aimed at life sciences work in universities. The plan matters because it lowers the cost barrier for researchers who want access to the company’s specialized biology model and its associated workbench tools, while keeping model use behind trusted-access approval.

Evidence and context

In a post dated October 15, 2026 and published on OpenAI’s site, the company said eligible academic labs can receive up to 30 Business Standard seats at no cost for up to 12 months. Access to GPT-Rosalind itself is subject to trusted-access approval, and the company said research data shared through the plan is not used to train its models by default. OpenAI also said the program includes access to commercially available frontier models within plan usage limits, but not API access.

The company described GPT-Rosalind as a dedicated life sciences model designed for deeper reasoning on biological questions, with Rosalind Workbench providing specialized tool orchestration across medicinal chemistry, genomics, wet-lab assistance and related scientific workflows. OpenAI said the plan is currently available to academic labs at U.S. universities, with principal investigators and lab leads able to apply on behalf of their labs if they do not already have an OpenAI Enterprise agreement. Labs at universities with an existing agreement are routed through the institution’s Enterprise access process.

OpenAI said it verifies institutional legitimacy, the PI or lab lead’s identity, professional background and authority to oversee lab access before activation. It also said it reviews the lab’s affiliation, research activities and intended use, and establishes responsibilities for the lab lead and an institutional safety contact. After activation, the company said safeguards continue through monitoring and enforcement, with additional checks for registered high-sensitivity use cases.

The plan builds on GPT-Rosalind’s earlier rollout. OpenAI said on September 11, 2026 that the model had exited research preview and become available globally to eligible organizations through its trusted-access program, and that published pricing took effect on October 5, 2026. OpenAI previously said on June 3, 2026 that it added stronger medicinal chemistry, genomics and wet-lab reasoning, along with research and sequencing-analysis plugins.

OpenAI framed the academic plan as part of a broader effort to put specialized AI tools into more scientists’ hands, citing areas such as protein design, neurodegeneration and drug discovery. The company did not provide a timeline for broader academic availability beyond U.S. university labs, and it did not announce any change to API access under the new plan.